Table 3.
Susceptibility pattern of ESBL-positive E. coli in pediatric UTI patients.
| Antibiotics | Test Done (TD) | Resistant N (%) |
95% CI Resistant |
Sensitive N (%) |
95% CI Sensitive |
Test Not Done (ND) |
|---|---|---|---|---|---|---|
| Amikacin | 13 | 1 (7.69) | 1.37–33.31 | 12 (92.31) | 66.69–98.63 | 1 |
| Ampicillin | 8 | 8 (100.00) | 67.56–100 | 0 (0.00) | 0–32.44 | 6 |
| Amoxicillin/clavulanic acid | 6 | 2 (33.33) | 9.68–70 | 4 (66.67) | 30–90.32 | 7 |
| Aztreonam | 11 | 11 (100.00) | 74.12–100 | 0 (0.00) | 0–25.88 | 3 |
| Cefepime | 13 | 13 (100.00) | 77.19–100 | 0 (0.00) | 0–22.81 | 1 |
| Cefoxitin | 2 | 2 (100.00) | 34.24–100 | 0 (0.00) | 0–65.76 | 12 |
| Ceftazidime | 3 | 3 (100.00) | 43.85–100 | 0 (0.00) | 0–56.15 | 11 |
| Ceftriaxone | 9 | 9 (100.00) | 70.09–100 | 0 (0.00) | 0–29.91 | 5 |
| Cefuroxime | 3 | 3 (100.00) | 43.85–100 | 0 (0.00) | 0–56.15 | 11 |
| Cephalothin | 2 | 2 (100.00) | 34.24–100 | 0 (0.00) | 0–65.76 | 12 |
| Ciprofloxacin | 11 | 8 (72.73) | 43.44–90.25 | 3 (27.27) | 9.75–56.56 | 3 |
| Sulfamethoxazole/trimethoprim | 9 | 3 (33.33) | 12.06–64.58 | 6 (66.67) | 35.42–87.94 | 5 |
| Gentamicin | 11 | 7 (63.64) | 35.38–84.83 | 4 (36.36) | 15.17–64.62 | 3 |
| Imipenem | 11 | 0 (0.00) | 0–25.88 | 11 (100.00) | 74.12–100 | 3 |
| Levofloxacin | 2 | 2 (100.00) | 34.24–100 | 0 (0.00) | 0–65.76 | 0 |
| Meropenem | 11 | 0 (0.00) | 0–25.88 | 11 (100.00) | 74.12–100 | 3 |
| Nitrofurantoin | 13 | 0 (0.00) | 0–22.81 | 13 (100.00) | 77.19–100 | 1 |
| Norfloxacin | 1 | 0 (0.00) | 0–79.35 | 1 (100.00) | 20.65–100 | 13 |
| Tazocin | 13 | 1 (7.69) | 1.37–33.31 | 12 (92.31) | 66.69–98.63 | 1 |
Table legend text. TD = respective antibiotic tested against ESBL-positive E. coli; ND = respective antibiotic was not tested against ESBL-positive E. coli.